- Sanofi (NASDAQ:SNY) and GlaxoSmithKline (NYSE:GSK) to initiate a new Phase 2 study with 720 volunteers aged 18 and over to select the most appropriate antigen dosage for Phase 3 evaluation of their adjuvanted recombinant protein COVID-19 vaccine candidate.
- Two injections will be given 21 days apart and three different antigen doses with a fixed dose of adjuvant will be tested.
- If results are positive, the Phase 3 study will start in Q2, with vaccine expected to be available in Q4.
- In parallel, development work on new SARS-CoV-2 variants is underway. A timeline on COVID-19 vaccine candidates can be seen below.
- In December 2020, Phase 1/2 study results showed an "insufficient" response in older adults, likely due to an inadequate concentration of the antigen.
- Sanofi earlier announced an agreement with Pfizer-BioNTech under which it will support the manufacturing and supply of more than 125M doses their COVID-19 vaccine.
